EDX Medical launches AI breast cancer test to assess recurrence risk

EDX Medical Group plc

EDX Medical Group (AIM: EDX) has launched the Caris MI Clarity breast cancer test in the UK through an agreement with US-based Caris Life Sciences.

The test uses artificial intelligence to assess the risk of breast cancer returning over both the short and long term, providing clinicians with an assessment covering up to 15 years from diagnosis.

MI Clarity is designed for postmenopausal women with early-stage, hormone receptor-positive (HR-positive), HER2-negative breast cancer that has not spread to nearby lymph nodes.

The test analyses tumour tissue images alongside clinical and molecular data to classify patients as having either a low or high risk of distant recurrence. It provides separate assessments for two periods: the first five years after diagnosis and the subsequent ten years.

This combined approach is intended to give doctors a clearer picture of how recurrence risk may change over time. Existing tests often assess early and late recurrence risk separately, which can add complexity to treatment planning.

The assessment is carried out at the time of initial diagnosis, when clinicians are considering treatment options. By providing both short-term and longer-term risk estimates in a single report, MI Clarity could help inform decisions about treatment and ongoing patient care.

The test has been validated using clinical data from tens of thousands of participants in clinical trials. EDX Medical says it could benefit up to 20,000 postmenopausal women in the UK each year.

The company also states that results can be provided within three days, compared with several weeks for some existing testing approaches.

Professor Sir Chris Evans, founder and chief scientific officer of EDX Medical, said the test would give patients and doctors additional information about the risk of the disease returning, supporting risk assessment and treatment planning.

Dr Mike Hudson, chief executive of EDX Medical, said MI Clarity would add to the company’s portfolio of diagnostic products designed to support clinical decisions.

George W. Sledge, chief medical officer at Caris Life Sciences, said the test brings early and late distant recurrence risk assessments together at the point of initial diagnosis, using AI to analyse tumour pathology samples alongside clinical data.

EDX Medical Group plc (LON:EDX) is a UK-based listed company focused on the development of diagnostic tests that enable personalised treatment for cancer, cardiovascular and infectious diseases.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

EDX Medical launches AI breast cancer test to assess recurrence risk

EDX Medical has launched the Caris MI Clarity AI breast cancer test in the UK, providing recurrence risk assessments...

EDX Medical appoints Martin Walton as Chief Executive Officer

EDX Medical has appointed Martin Walton as CEO with immediate effect, succeeding co-founder Dr Michael Hudson, who will continue...

EDX Medical adds diagnostics experts to Board as company targets commercial growth

EDX Medical Group has appointed Dr Joanne Hackett and Peter Collins as non-executive directors, bringing senior expertise in diagnostics,...

EDX Medical launches AI breast cancer test in UK

EDX Medical Group has partnered with Caris Life Sciences to introduce the Caris MI Clarity test in the UK....

EDX Medical Founder increases shareholding with 197,500 share purchase

EDX Medical founder and Chief Scientific Officer Professor Sir Christopher Evans has bought 197,500 shares in the company, taking...

EDX Medical Founder Sir Christopher Evans to present at London investor event

EDX Medical Group has announced that Founder and Chief Scientific Officer Professor Sir Christopher Evans OBE will present at...

Search